BS Summary: This article contains 7 faulty reasoning types, including Biased Writer Voice, Negativity Bias, and Framing Effect, with Attempt to Sell a Product or Service as the most egregious example at 20.6% saturation with 58 hits. Analysis detected 187 faulty-reasoning hits from 282 analyzed words, generating a BS Score of 41% and a BS Rank of 32% (14,927 of 21,886 articles). This article is better (less manipulative) than 68.20% of the article peer group.
AstraZeneca, Ionis report major trial failure with heart disease drug
The drug didn’t outperform placebo in a condition known as ATTR-CM
Europe Correspondent
Andrew covers the biopharma industry, scientific research, and public health across the continent.
You can reach Andrew confidentially on Signal at drewqjoseph.71.
LONDON — In a blow to its cardiovascular aspirations, AstraZeneca said Thursday that its drug for a heart disease — one that has become an increasingly competitive target for biopharma companies — failed in a pivotal trial.
The drug, called Wainua, on which AstraZeneca is partnered with Ionis Pharmaceuticals, did not outperform placebo in reducing cardiovascular death and clinical events for patients with a condition known as ATTR-CM, or transthyretin-mediated amyloid cardiomyopathy.
AstraZeneca’s U.S. shares were down some 8% in premarket trading, while its London-listed shares were down 9% early Thursday.
Ionis shares, meanwhile, were down 12% in premarket hours.
STAT+ Exclusive Story
Already have an account?
Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Totals $468 per year
for 3 months, then $399/year
Savings start at 25%!
$300 Annually per user
To read the rest of this story subscribe to STAT+.
cardiology , drug development , Pharmaceuticals , STAT+
Submit a correction request Reprints
STAT Plus: Roche ends Huntington’s gene-silencing programs
STAT Plus: ARPA-H launches $160 million effort to develop custom gene editing drugs
STAT Plus: Prime wins Beam arbitration, clearing path to clinic
Adam's Biotech Scorecard
STAT Plus: 931 days.
The drug approval scandal hiding in plain sight
STAT Plus: The quest to save Grace — and clear the way for rare disease patients everywhere
Speakers
3speakers43%attributed speech162writer words
Voice mapSelect a segment to jump to its words
Selected voice
97%flagged-word coverageAstraZeneca
38 attributed words32% of attributed speech25% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.